![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » VAXGEN RAISES $79M THROUGH SALE OF INTEREST IN OVERSEAS BIOPHARMACEUTICAL MANUFACTURING FACILITY
VAXGEN RAISES $79M THROUGH SALE OF INTEREST IN OVERSEAS BIOPHARMACEUTICAL MANUFACTURING FACILITY
June 29, 2006
VaxGen, Inc. announced today that it has realized gross proceeds of approximately $79.0 million through the sale of a portion of its common shares in Celltrion, Inc. VaxGen also granted the purchasers an exclusive option to acquire the remainder of its Celltrion shares by December 31, 2006.
Yahoo News (http://biz.yahoo.com/prnews/060629/sfth045.html?.v=61)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct